J. G. Maring

TL;DR: This study demonstrated that in 59% of the cases, a decreased DPD activity could be detected in peripheral blood mononuclear cells and demonstrated that at least 57% (8 of 14) of the patients with a reduced D PD activity have a molecular basis for their deficient phenotype.

TL;DR: In this review, proteins relevant for the efficacy and toxicity of pyrimidine antagonists will be summarised, and the role of germline polymorphisms, tumour-specific somatic mutations and protein expression levels in the metabolic pathways and clinical pharmacology of these drugs are described.

TL;DR: It is demonstrated that a genomic deletion affecting DPYD and a deep intronic mutation affecting pre-mRNA splicing can cause severe 5FU-associated toxicity, and screening for DPD deficiency should include a search for genomic rearrangements and aberrant splicing.

TL;DR: This data indicates that drug‐related problems of polypharmacy patients in Dutch nursing homes are more likely to be related to substance abuse than to underlying causes of disease.

TL;DR: The results indicate that the inactivation of one dihydropyrimidine dehydrogenase allele can result in a strong reduction in 5-fluorouracil clearance, causing severe 5- fluoroursacil induced toxicity.